The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
CMOs showed an increasing reluctance to take on debt in 2022
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Advances clinical research capabilities with leading regulatory grade registries platform
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Subscribe To Our Newsletter & Stay Updated
